<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03200860</url>
  </required_header>
  <id_info>
    <org_study_id>2017-001679-22</org_study_id>
    <nct_id>NCT03200860</nct_id>
  </id_info>
  <brief_title>Effects of Empagliflozin on Clinical Outcomes in Patients With Acute Decompensated Heart Failure</brief_title>
  <acronym>EMPA-RESPONSE</acronym>
  <official_title>Randomized, Double Blind, Placebo Controlled, Multicenter Pilot Study on the Effects of Empagliflozin on Clinical Outcomes in Patients With Acute Decompensated Heart Failure (EMPA-RESPONSE-AHF)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Medical Center Groningen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Medical Center Groningen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Acute decompensated heart failure is the fastest growing disease in the world and the leading
      cause of hospital admissions worldwide. Short term mortality and rehospitalization are
      extremely high (20-30% within 3-6 months) and there is no therapy available that improves
      clinical outcome in these patients. Empagliflozin is a selective inhibitor of sodium glucose
      co-transporter with diuretic and renal- protective properties. In patients with type 2
      diabetes at high risk for cardiovascular events, empagliflozin reduced the risk of
      hospitalization for heart failure by 35%. Based on the promising pharmacological profile of
      empagliflozin in relation to the needs for treatment of acute decompensated heart failure, we
      hypothesize that empagliflozin exerts positive effects in acute decompensated heart failure,
      with or without diabetes,

      This is a randomized, placebo-controlled, double-blind, parallel group, multicenter study in
      subjects admitted for acute decompensated heart failure. Eighty eligible subjects will be
      randomized in a 1:1 ratio to receive either empagliflozin 10 mg/day or matched placebo.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, placebo-controlled, double-blind, parallel group, multicenter study in
      subjects admitted for acute decompensated heart failure. Eighty eligible subjects will be
      randomized in a 1:1 ratio to receive either empagliflozin 10 mg/day or matched placebo.

      Treatment will be continued until 30 days after index event, and primary efficacy
      measurements will be carried out during hospitalization and safety events until 60 days after
      index hospitalisation.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 18, 2017</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">May 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>randomized, placebo-controlled, double-blind, parallel group, multicenter study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>double blind, placebo controlled</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Dyspnea</measure>
    <time_frame>From baseline to Day 4</time_frame>
    <description>Change in Dyspnea on VAS analogue scale (AUC)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Diuretic Response</measure>
    <time_frame>Total weight change from baseline to Day 4</time_frame>
    <description>Weight change from baseline per 40 mg of Furosemide equivalent</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Length of Stay</measure>
    <time_frame>within 60 days</time_frame>
    <description>Hospital stay of Index admission</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma NTproBNP</measure>
    <time_frame>From baseline to Day 4</time_frame>
    <description>Change in NTproBNP</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Death and/or heart failure re-admission</measure>
    <time_frame>Day 30</time_frame>
    <description>All Cause Mortality or HF readmission</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in creatinine</measure>
    <time_frame>Day 4 (or discharge if earlier) and Day 30</time_frame>
    <description>in mg/dL or umol/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in eGFR</measure>
    <time_frame>Day 4 (or discharge if earlier) and Day 30</time_frame>
    <description>in mL/min/1.73m2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in cystatin C</measure>
    <time_frame>Day 4 (or discharge if earlier) and Day 30</time_frame>
    <description>in mg/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in BUN</measure>
    <time_frame>Day 4 (or discharge if earlier) and Day 30</time_frame>
    <description>in mg/dL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in hemoglobin</measure>
    <time_frame>Day 4 (or discharge if earlier) and Day 30</time_frame>
    <description>in g/dL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in hematocrit</measure>
    <time_frame>Day 4 (or discharge if earlier) and Day 30</time_frame>
    <description>in %</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in albumin</measure>
    <time_frame>Day 4 (or discharge if earlier) and Day 30</time_frame>
    <description>g/dL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in urinary sodium excretion</measure>
    <time_frame>Day 4 (or discharge if earlier) and Day 30</time_frame>
    <description>mmol/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in urinary albumin to creatinine ratio (UACR)</measure>
    <time_frame>Day 4 (or discharge if earlier) and Day 30</time_frame>
    <description>mg/g cr</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in N-acetyl-beta-D-glucosaminase (NAG)</measure>
    <time_frame>Day 4 (or discharge if earlier) and Day 30</time_frame>
    <description>U/g Cr</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Neutrophil Gelatinase Associated Lipocalin (NGAL)</measure>
    <time_frame>Day 4 (or discharge if earlier) and Day 30</time_frame>
    <description>mg/g Cr</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Kidney Injury Molecule 1 (KIM-1)</measure>
    <time_frame>Day 4 (or discharge if earlier) and Day 30</time_frame>
    <description>ng/gCr</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Serious adverse events</measure>
    <time_frame>60 days</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Heart Failure Acute</condition>
  <condition>Heart Failureï¼ŒCongestive</condition>
  <condition>Heart Failure; With Decompensation</condition>
  <arm_group>
    <arm_group_label>Empagliflozin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Empagliflozin 10 mg daily, oral, 30 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching Placebo 10 mg daily, oral, 30 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Empagliflozin 10 MG</intervention_name>
    <description>10 mg daily, oral, 30 days</description>
    <arm_group_label>Empagliflozin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Oral Tablet</intervention_name>
    <description>Matching Placebo, 10 mg daily, oral, 30 days</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female &gt;18 years of age; Women of non-child-bearing potential must have a
             documentation of surgical sterilization (hysterectomy and/or bilateral oophorectomy)
             OR must have experienced menopause (no menses for &gt;12 months). Women of child bearing
             potential must have a negative pregnancy test, AND must use highly effective methods
             of contraception during treatment with IP plus 5 days after the end of study drug
             administration.

          -  Hospitalized for AHF; AHF is defined as including all of the followings measured at
             any time between presentation (including the emergency department) and the end of
             screening:

               1. Dyspnea at rest or with minimal exertion

               2. Signs of congestion, such as edema, rales, and/or congestion on chest radiograph

               3. BNP â‰¥350 pg/mL or NT-proBNP â‰¥1,400 pg/mL (for patients with AF: BNPâ‰¥500 pg/mL or
                  NT-proBNP â‰¥2,000 pg/mL)

               4. Treated with loop diuretics at screening

          -  Able to be randomized within 24 hours from presentation to the hospital

          -  Able and willing to provide freely given written informed consent

          -  eGFR (CKD-EPI) â‰¥30 ml/min/1.73m2 between presentation and randomization

        Exclusion Criteria:

          -  Diabetes Mellitus Type I

          -  Dyspnea primarily due to non-cardiac causes

          -  Cardiogenic shock

          -  Acute coronary syndrome within 30 days prior to randomization

          -  Planned or recent percutaneous or surgical coronary intervention within 30 days prior
             to randomization

          -  Signs of keto-acidosis and/or hyperosmolar hyperglaecemic syndrome (pH&gt;7.30 and
             glucose &gt;15 mmol/L and HCO3&gt;18 mmol/L)

          -  Pregnant or nursing (lactating) women

          -  Current participation in any interventional study

          -  Inability to follow instructions or comply with follow-up procedures

          -  Any other medical conditions that may put the patient at risk or influence study
             results in the investigator's opinion, or that the investigator deems unsuitable for
             the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Adriaan Voors, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Medical Center Groningen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kevin Damman, Dr.</last_name>
    <phone>0031503616161</phone>
    <email>k.damman@umcg.nl</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Medical Center Groningen</name>
      <address>
        <city>Groningen</city>
        <zip>9700RB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kevin Damman, MD,PhD</last_name>
      <phone>0031503616161</phone>
    </contact>
    <investigator>
      <last_name>Kevin Damman, MD,PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <reference>
    <citation>Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ, Broedl UC, Inzucchi SE; EMPA-REG OUTCOME Investigators. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med. 2015 Nov 26;373(22):2117-28. doi: 10.1056/NEJMoa1504720. Epub 2015 Sep 17.</citation>
    <PMID>26378978</PMID>
  </reference>
  <reference>
    <citation>Wanner C, Inzucchi SE, Lachin JM, Fitchett D, von Eynatten M, Mattheus M, Johansen OE, Woerle HJ, Broedl UC, Zinman B; EMPA-REG OUTCOME Investigators. Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. N Engl J Med. 2016 Jul 28;375(4):323-34. doi: 10.1056/NEJMoa1515920. Epub 2016 Jun 14.</citation>
    <PMID>27299675</PMID>
  </reference>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 23, 2017</study_first_submitted>
  <study_first_submitted_qc>June 26, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 27, 2017</study_first_posted>
  <last_update_submitted>December 19, 2017</last_update_submitted>
  <last_update_submitted_qc>December 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Medical Center Groningen</investigator_affiliation>
    <investigator_full_name>A.A.Voors</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>heart failure</keyword>
  <keyword>diuretic response</keyword>
  <keyword>empagliflozin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Empagliflozin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

